FARYDAK (panobinostat), antineoplastic agent

• FARYDAK has Marketing Authorisation in the treatment of relapsed and/or refractory multiple myeloma, in combination with bortezomib and dexamethasone in patients who have already received at least two prior lines of treatment including bortezomib and an immunomodulatory agent.
• Its efficacy on the overall response rate, evaluated from noncomparative data, was modest after 8 cycles of treatment. It is intended as a backup therapy. The toxicity of the combination of panobinostat with bortezomib and with dexamethasone, especially gastrointestinal and haematological, is significant.

-